Scalper1 News
Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street’s Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron’s earnings, excluding one-time items, rose 5% over the year-earlier quarter to $2.52 a share, missing analysts’ consensus by 5 cents, according to Thomson Reuters. Revenue rose 22% to $726 million, missing the Street’s Scalper1 News
Scalper1 News